HCM
BSX icon

Highline Capital Management’s Boston Scientific BSX Stock Holding History

Highline Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,033,561
Closed -$46.7M – 26
2019
Q4 		$46.7M Buy
+1,033,561
New +$43.2M 7.4% 3

Other funds holding BSX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.39B AUM 1.06% 1-Year Est. Return

Highline Capital Management's BSX Position: Q1 2020 in Review

Highline Capital Management sold out of Boston Scientific (BSX) in Q1 2020, closing a stake of 1,033,561 shares — an estimated $46.7M sold.

Highline Capital Management first reported a position in BSX in Q4 2019 and held it in 1 quarter. The position peaked at $46.7M in Q4 2019. 800 funds tracked by Wall St. Rank hold BSX as of Q1 2020.

  • Highline Capital Management reported no remaining Boston Scientific position as of Q1 2020 after selling out during the quarter.
  • Highline Capital Management sold 1,033,561 Boston Scientific shares in Q1 2020, an estimated $46.7M.
  • Highline Capital Management first reported a position in Boston Scientific in Q4 2019 and held it in 1 quarter.
  • Highline Capital Management's Boston Scientific position peaked at $46.7M in Q4 2019.
  • 800 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2020.

Based on Highline Capital Management's 13F filing for Q1 2020, filed 15 May 2020.